

GSK-3 β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Modulatory Properties

Biology

10, 610

DOI: [10.3390/biology10070610](https://doi.org/10.3390/biology10070610)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Differential expression of regulators of the canonical Wnt pathway during the compensatory beta-cell hyperplasia in prediabetic mice. <i>Biochemical and Biophysical Research Communications</i> , 2022, 611, 183-189.	1.0	0
2	Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. <i>Cells</i> , 2022, 11, 1812.	1.8	5
3	Combination Approaches to Target PD-1 Signaling in Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
4	Long non-coding RNA 01614 hyperactivates WNT/ β -catenin signaling to promote pancreatic cancer progression by suppressing GSK-3 β . <i>International Journal of Oncology</i> , 2022, 61, .	1.4	9
5	Glycogen synthase kinase-3 β inhibitors as a novel promising target in the treatment of cancer: Medicinal chemistry perspective. <i>Results in Chemistry</i> , 2022, 4, 100532.	0.9	3
6	PPA1, an energy metabolism initiator, plays an important role in the progression of malignant tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4